Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.48 |
| ▸ | PPARA | Q07869 | 4/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30003962 | 1.00 | PPARG (0.48) | PPARGPPARAAPPMAOBKMT2A | |
| SCHEMBL21839363 | 1.00 | PPARG (0.48) | PPARGPPARAAPPMAOBKMT2A | |
| SCHEMBL21855311 | 1.00 | PPARG (0.48) | PPARGPPARAAPPMAOBKMT2A | |
| SCHEMBL30767153 | 1.00 | PPARG (0.48) | PPARGPPARAAPPMAOBKMT2A | |
| SCHEMBL30004111 | 1.00 | PPARG (0.48) | PPARGPPARAAPPMAOBKMT2A | |
| SCHEMBL21855405 | 0.94 | PPARG (0.50) | PPARGPPARAMAOBKMT2AACHE | |
| SCHEMBL21839369 | 0.83 | MAOB (0.49) | PPARGPPARAAPPMAOBKMT2A | |
| SCHEMBL21839370 | 0.83 | MAOB (0.49) | PPARGPPARAAPPMAOBKMT2A | |
| SCHEMBL21855309 | 0.83 | MAOB (0.49) | PPARGPPARAAPPMAOBKMT2A | |
| SCHEMBL28277355 | 0.81 | LCK (0.44) | LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3863999-A1 | A SERIES OF COMPOUNDS FOR TREATMENT OF SKIN DISEASES AND OTHER CONDITIONS | Unigen, Inc. (US) | 2021-08-18 | — | — | EP | claimed |
| WO-2020081405-A1 | A SERIES OF COMPOUNDS FOR TREATMENT OF SKIN DISEASES AND OTHER CONDITIONS | UNIGEN, INC (US) | 2020-04-23 | — | — | WO | claimed |
| US-20220411356-A1 | Series of Compounds for Treatment of Skin Diseases and Other Conditions | UNIGEN, INC. (US) | 2022-12-29 | — | — | US | disclosed |
| EP-3863999-A1 | A SERIES OF COMPOUNDS FOR TREATMENT OF SKIN DISEASES AND OTHER CONDITIONS | Unigen, Inc. (US) | 2021-08-18 | — | — | EP | disclosed |
| WO-2020081405-A1 | A SERIES OF COMPOUNDS FOR TREATMENT OF SKIN DISEASES AND OTHER CONDITIONS | UNIGEN, INC (US) | 2020-04-23 | — | — | WO | disclosed |
| US-20200115307-A1 | Series of Compounds for Treatment of Skin Diseases and Other Conditions | UNIGEN, INC. (US) | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411356-A1 | Series of Compounds for Treatment of Skin Diseases and Other Conditions | TYR, MC1R, MPO | PPARG 48/4885PPARA 137/4885APP 3251/4885 |
| US-20200115307-A1 | Series of Compounds for Treatment of Skin Diseases and Other Conditions | TYR, MC1R, MPO | PPARG 48/4885PPARA 137/4885APP 3251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.